1-4 of 4
Huayuan Zhu, MD
Close
Sort by
Journal Articles

Preliminary Results from a Phase I, First-in-Human Study of YY-20394, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies

Junyuan Qi, PhD, Yuqin Song, MD PhD, Bo Jiang, PhD, Jianyong Li, PhD, Meifeng Tu, PhD, Lingyan Ping, MD PhD, Zengjun Li, PhD, Wei Xu, MD PhD, Huayuan Zhu, MD PhD, Jun Zhu, MD PhD, Hanying Bao, MD PhD, Zusheng Xu, PhD, Lugui Qiu, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5332.
https://doi.org/10.1182/blood-2018-99-110585
Published: 2018
Journal Articles

TP53-Induced Glycolysis and Apoptosis Regulator Protects from Spontaneous Apoptosis and Predicts Poor Prognosis in Chronic Lymphocytic Leukemia

Ming Hong, Yi Xia, Yu Zhu, MD, Huihui Zhao, Yue Xie, Lei Fan, MD, PhD, Li Wang, Kourong Miao, MD, Wei Wu, Huayuan Zhu, MD, Yaoyu Chen, Wei Xu, Sixuan Qian, Jianyong Li
Journal: Blood
Blood (2016) 128 (22): 5101.
https://doi.org/10.1182/blood.V128.22.5101.5101
Published: 2016
Journal Articles

Clinical Features of Chinese Patients with Paroxysmal Nocturnal Hemoglobinuria Diagnosed By FLAER

Jing Li, MD, Haiying Hua, MD, Weyi Shen, MD, Guangsheng He, MD, Huayuan Zhu, MD, Shuai Wang
Journal: Blood
Blood (2015) 126 (23): 4544.
https://doi.org/10.1182/blood.V126.23.4544.4544
Published: 2015
Journal Articles

Priming Regiments Based on Idarubicin, or Aclacinomycin or Pirarubicin Combining with Cytarabine and Granulocyte-Colony Stimulating Factor for Reinduction of Refractory/Relapsed Acute Lymphoblastic Leukemia

Yu Zhu, MD, Guangsheng He, MD, Kourong Miao, MD, Huayuan Zhu, MD, Weyi Shen, MD, Wang Shuai
Journal: Blood
Blood (2015) 126 (23): 4550.
https://doi.org/10.1182/blood.V126.23.4550.4550
Published: 2015